Barbados health ministry addresses insulin supply concerns
Amid concerns over insulin shortages in Barbados, the Ministry of Health and Wellness reassures the public that while there is a scarcity of Humulin 70/30 due to supply challenges, there is no overall shortage of any therapeutic class of insulin on the island.
Commitment to continuous care
In a recent statement, the ministry emphasized its commitment to providing an uninterrupted supply of quality insulin products for all Barbadians at an affordable cost.
Through the Barbados Drug Service (BDS), efforts are underway to ensure accessibility to a range of insulin brands, with the Barbados National Drug Formulary (BNDF) currently listing 13 available options.
Guidance for patients
Acknowledging the current scarcity of Humulin 70/30, the ministry advised patients to consult with their physicians for suitable alternative options.
To safeguard the long-term care of insulin-dependent diabetics and ensure the financial sustainability of the national program, the ministry announced policy changes regarding the maximum quantity of insulin pens covered by the BDS.
Policy changes
Effective immediately, the BDS will cover the cost of a maximum of two pens per client per month for each allowed therapeutic class.
While protocols for other insulin types remain unchanged, the ministry assured that comparable options are available across all therapeutic classes to meet patients’ needs adequately.
Understanding insulin’s vital role
Insulin plays a crucial role in the treatment and management of diabetes mellitus type-1 and type-2, both of which pose significant health risks, including coronary artery disease, stroke, and peripheral vascular disease.
